Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma

NCT02500797 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02500797
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02500797 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
August 13, 2015
Completion date
April 1, 2023
Enrollment
164 (actual)
Sites
651

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced bone sarcoma, locally advanced dedifferentiated liposarcoma, locally advanced gastrointestinal stromal tumor, locally advanced soft tissue sarcoma, metastatic bone sarcoma, metastatic liposarcoma, metastatic soft tissue sarcoma, metastatic undifferentiated pleomorphic sarcoma, metastatic unresectable sarcoma, pleomorphic liposarcoma, stage iii bone sarcoma ajcc v7, stage iii soft tissue sarcoma ajcc v7, stage iv bone sarcoma ajcc v7, stage iv soft tissue sarcoma ajcc v7, stage iva bone sarcoma ajcc v7, stage ivb bone sarcoma ajcc v7, unresectable bone sarcoma, unresectable dedifferentiated liposarcoma, unresectable liposarcoma, unresectable malignant gastrointestinal stromal tumor, unresectable soft tissue sarcoma